Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2652W HIGH $3.20
Volume
652.00
Value Traded
300.33 K
Short % Float
0.12%
-5.44%Week
-4.14%1 Month
-17.75%3 Month
-7.95%6 Month
-63.78%5 Year
-63.78%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
73.47 M
EPS (TTM)
-0.13
P/E Ratio
-
Ent. Value
79.70 M
Total Shares
52.45 M
Float Shares
35.64 M
Insiders
32.09%
Institutions
20.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OKYO Catalyst Timeline
Dated clinical, regulatory and corporate events for OKYO Pharma Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for OKYO Pharma Limited
256Total events
5Upcoming
45Tier-1 (high impact)
2020 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment UpdateurcosimodTrial
First patients enrolled in Phase 3 NEPTUNE trial of urcosimod for NCP
neuropathic corneal painsource ↗
◆R&D DayPresentation
OKYO leadership team to engage optometric experts at American Academy of Optometry
●Oral PresentationurcosimodPresentation
OKYO Pharma to present at 5th Annual ESCRS iNovation Day
neuropathic corneal painsource ↗
●R&D DayPresentation
OKYO Pharma to participate in fireside chat at Cantor Global Healthcare Conference
●Oral PresentationurcosimodPresentation
OKYO Pharma to present at Ophthalmology Futures European Forum
neuropathic corneal painsource ↗
▲FDA Feedback ReceivedurcosimodFDA Meeting
FDA Type D meeting provided positive feedback validating regulatory and clinical path for urcosimod
neuropathic corneal painsource ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
neuropathic corneal pain (NCP) and anterior segment eye diseasessource ↗
●Quarterly UpdateCorporate
Filing of Annual Report on Form 20-F for fiscal year ended March 31, 2026
◆Oral PresentationPresentation
Participation in Piper Sandler 2026 Virtual Ophthalmology Symposium
▲Type D MeetingurcosimodFDA Meeting
Positive FDA Type D meeting feedback validating regulatory path for urcosimod
neuropathic corneal painsource ↗
▲Trial CompletionurcosimodTrial
Completed phase 2 trial of urcosimod in NCP
neuropathic corneal pain (NCP)source ↗
◆Trial InitiationurcosimodTrial
Initiate ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP
neuropathic corneal painsource ↗
◆Poster PresentationurcosimodPresentation
Poster presentation at ARVO: First-in-Human Study of Urcosimod Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients
Neuropathic Corneal Pain (NCP)source ↗
◆Poster PresentationurcosimodPresentation
Abstract accepted for presentation at ARVO 2026 Annual Meeting
neuropathic corneal pain (NCP)source ↗
◆Oral PresentationPresentation
CEO presentation at Eyecelerator: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Corneal and Anterior Segment Diseasessource ↗
◆Oral PresentationurcosimodPresentation
Abstract accepted for presentation at ASCRS 2026 Annual Meeting
neuropathic corneal painsource ↗
▲Topline ReadouturcosimodClinical Data
Positive Phase 2a data for urcosimod in NCP pain reduction
neuropathic corneal painsource ↗
▲Full ResultsurcosimodClinical Data
New Phase 2 data demonstrating meaningful improvements in patient-reported quality of life outcomes with urcosimod in neuropathic corneal pain
neuropathic corneal painsource ↗
▲Topline ReadouturcosimodClinical Data
Positive Phase 2a proof-of-concept results for urcosimod in NCP
neuropathic corneal pain (NCP)source ↗
▲Primary Endpoint MeturcosimodClinical Data
Successful Phase 2 trial of urcosimod in NCP completed
neuropathic corneal painsource ↗
▲Trial CompletionurcosimodTrial
Successful Phase 2 trial of urcosimod in NCP completed
neuropathic corneal painsource ↗
▼Equity OfferingCorporate
Completed public offering raising approximately $22 million in gross proceeds
▲Type C MeetingurcosimodFDA Meeting
Successful Type C meeting with FDA regarding Phase 2b/3 trial of urcosimod for NCP
neuropathic corneal painsource ↗
▲IND ClearanceurcosimodIND
FDA authorizes single-patient expanded access IND for urcosimod in neuropathic corneal pain
neuropathic corneal painsource ↗
◆Trial InitiationurcosimodTrial
Initiation of Phase 2b/3 multiple-dose study of urcosimod in NCP
neuropathic corneal pain (NCP)source ↗
▲FDA Feedback ReceivedurcosimodFDA Meeting
Positive FDA feedback from Type D meeting supporting single-trial approval pathway
neuropathic corneal painsource ↗
▲Topline ReadouturcosimodClinical Data
Positive Phase 2 results for urcosimod in neuropathic corneal pain
neuropathic corneal pain (NCP)source ↗
●Trial CompletionurcosimodTrial
Phase 2 trial of urcosimod for dry eye disease completed
dry eye diseasesource ↗
▲Trial CompletionurcosimodTrial
Phase 2 trial of urcosimod in NCP completed
neuropathic corneal painsource ↗
▲Full ResultsurcosimodClinical Data
New corneal nerve data from Phase 2 trial of urcosimod
neuropathic corneal painsource ↗
◆Trial CompletionurcosimodTrial
Phase 2 trial of urcosimod for dry eye disease completed
dry eye diseasesource ↗
◆Oral PresentationurcosimodPresentation
OKYO Pharma to present at OIS XV in San Diego
neuropathic corneal painsource ↗
◆Trial CompletionurcosimodTrial
Phase 2 trial of urcosimod for neuropathic corneal pain completed
neuropathic corneal painsource ↗
◆Oral PresentationurcosimodPresentation
Presentation at BIO-Europe 2025
neuropathic corneal painsource ↗
◆Trial CompletionurcosimodTrial
Phase 2 trial of urcosimod for dry eye disease completed
dry eye diseasesource ↗
◆Topline ReadoutOK-101Clinical Data
Top-line data from Phase 2a NCP trial
neuropathic corneal painsource ↗
▲Fast Track DesignationurcosimodDesignation
FDA Fast Track Designation granted for urcosimod in NCP
neuropathic corneal pain (NCP)source ↗
▲Topline ReadouturcosimodClinical Data
Strong topline results from Phase 2 proof-of-concept trial in 18 NCP patients
neuropathic corneal pain (NCP)source ↗
▲Equity OfferingCorporate
Received $1.9 million non-dilutive funding to accelerate urcosimod development
●Trial CompletionurcosimodTrial
Phase 2 trial of urcosimod for neuropathic corneal pain completed
neuropathic corneal painsource ↗
Past FDA Catalysts and PDUFA Decisions
How OKYO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-03 | Urcosimod (formerly called OK-101) | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$37M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.5x
rNPV / MCap
Top 72%
Micro Cap(rank 474 of 658)
Percentile Rank
OKYO Pharma Limited faces pipeline headwinds (29/100), with $431M risk-adjusted pipeline value, led by Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeks in Neuropathic Corneal Pain (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeks Small moleculeNCT07838506 | Neuropathic Corneal Pain | Phase 3 | NOT YET_RECRUITING | 111 | Oct 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every OKYO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Urcosimod Fast Track | neuropathic corneal pain | Phase 2 | 2026-04-29 | positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients.Read More | OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Patil Rajkumar V.Officer (Chief Scientific Officer) | Buy | 3,363 20,030 held | $1.49 | 07/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OKYO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.1 % | 562.00 K | 375.20 K |
OKYO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OKYO ranks across every disease it competes in
Competitive Position is a premium feature
See how OKYO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOKYO News
OKYO▲ +0.7%today
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma has announced the enrollment of the first patients in its Phase 3 NEPTUNE trial for urcosimod, aimed at treating neuropathic corneal pain. This trial represents a significant step towards addressing the lack of FDA-approved therapies for this debilitating condition. The study will take place across multiple sites in the U.S. and Europe, evaluating the efficacy of urcosimod in improving ocular pain.
Read more →OKYOOKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
OKYO Pharma Limited will present at several upcoming ophthalmic conferences, including Eyecelerator and the American Academy of Ophthalmology. The company aims to engage with experts in optometry and ophthalmology to discuss neuropathic corneal pain (NCP) and anterior segment diseases. Additionally, OKYO plans to initiate a Phase 3 clinical trial for its investigational therapy, urcosimod.
Read more →OKYO▼ -5.2%on this news
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
OKYO Pharma Limited will present at the Ophthalmology Futures European Forum and the ESCRS iNovation Day in September 2026. The participation highlights the company's commitment to advancing its lead asset, urcosimod, through its Phase 3 NEPTUNE trial for neuropathic corneal pain. Recent FDA feedback has validated their regulatory path, and the company is in a strong financial position.
Read more →OKYOOKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
OKYO Pharma Limited will participate in the Cantor Global Healthcare Conference from September 9-11, 2026. The event will feature presentations from key executives and provide opportunities for one-on-one meetings. This participation follows positive feedback from the FDA regarding the company's regulatory path for urcosimod and a strengthened financial position.
Read more →OKYOOKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
OKYO Pharma Limited announced that its Chief Scientific Officer, Raj Patil, PhD, has purchased 3,363 shares, increasing his total holdings to 20,030 shares. The company is preparing to initiate a Phase 3 clinical trial for urcosimod, aimed at treating neuropathic corneal pain, with enrollment expected to begin in the second half of the year.
Read more →OKYO▲ +5.8%on this newsshared move
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
OKYO Pharma Limited announced its participation in the BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. The event will be held virtually, featuring key executives including the CEO and CFO. The company is also preparing to launch a Phase 3 trial for its investigational therapy for neuropathic corneal pain.
Read more →OKYOOKYO Pharma Announces Purchase of Shares by Director
OKYO Pharma Limited announced that Non-Executive Director John Brancaccio purchased 5,000 shares at $1.48 each, increasing his total holdings to 35,201 shares. The company is preparing to launch a Phase 3 clinical trial for its investigational therapy targeting neuropathic corneal pain. This trial will involve around 111 patients and is set to begin in the latter half of the year.
Read more →OKYOOKYO Pharma Announces Purchase of Shares by Chief Executive Officer
OKYO Pharma Limited announced that CEO Robert J. Dempsey purchased 15,000 shares at $1.54 each. The company is focused on developing therapies for neuropathic corneal pain and plans to start a Phase 3 clinical trial later this year, enrolling around 111 patients to evaluate urcosimod.
Read more →OKYOOKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
OKYO Pharma Limited announced that Gary S. Jacob, its Chief Development Officer and Director, has purchased an additional 3,500 shares at $1.40 each, increasing his total holdings to 112,420 shares. The company is preparing to launch a global Phase 3 clinical trial for urcosimod, aimed at treating neuropathic corneal pain, with plans to enroll around 111 patients.
Read more →OKYO▲ +5.6%on this newsshared move
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
OKYO Pharma Limited announced that its Chief Medical Officer, Flavio Mantelli, purchased 20,000 shares at $1.40 each. The company is preparing to initiate a global Phase 3 clinical trial for its investigational therapy, urcosimod, aimed at treating neuropathic corneal pain. This trial will involve approximately 111 patients and is set to begin in the second half of the year.
Read more →OKYO▲ +5.1%on this newsshared move
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYO Pharma Limited will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The presentation will be led by CEO Robert J. Dempsey and CMO Flavio Mantelli. The company is developing therapies for neuropathic corneal pain and plans to initiate a Phase 3 clinical trial for its investigational drug urcosimod.
Read more →OKYO▲ +5.1%on this newsshared move
OKYO Pharma Announces Purchase of Shares by Chairman
OKYO Pharma Limited announced that its Chairman, Gabriele Cerrone, has purchased 25,000 ordinary shares at $1.40 each, increasing his total holdings to 20.51% of the company's issued share capital. This move indicates Cerrone's confidence in the company's prospects. OKYO is also set to begin a Phase 3 clinical trial for its treatment of neuropathic corneal pain later this year.
Read more →OKYOOKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
OKYO Pharma has filed its Annual Report for the fiscal year ending March 31, 2026, highlighting a robust cash position and plans for the NEPTUNE Phase 3 trial. The company raised approximately $25 million, enhancing its financial resources to support the trial for urcosimod, aimed at treating neuropathic corneal pain. The NEPTUNE trial is set to begin in the second half of 2026, enrolling around 111 patients.
Read more →OKYO▼ -5.1%on this news
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
OKYO Pharma has received positive feedback from the FDA regarding its Type D meeting, which supports the advancement of urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain. The trial, named NEPTUNE, will enroll approximately 111 subjects and aims to address the unmet medical need in this area. The FDA's feedback also provides clarity on the regulatory strategy, potentially allowing for a streamlined development pathway.
Read more →OKYO▲ +8.7%on this newsshared move
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
OKYO Pharma Limited will participate in the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The event will feature CEO Robert J. Dempsey and CMO Flavio Mantelli. OKYO is focused on developing therapies for neuropathic corneal pain and has recently completed a Phase 2 trial for its drug urcosimod.
Read more →OKYOOKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
OKYO Pharma Limited has appointed Dr. Marta Sacchetti to its Scientific Advisory Board, enhancing its expertise in ocular inflammatory diseases. Dr. Sacchetti's extensive background in clinical and translational research will support OKYO's development strategy for neuropathic corneal pain treatments. The company recently reported positive results from its Phase 2 trials for its investigational therapy, Urcosimod.
Read more →OKYOOKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
OKYO Pharma Limited announced that CEO Robert J. Dempsey will present at the Eyecelerator conference, while CSO Raj Patil will present findings on Urcosimod at the ARVO Annual Meeting. Urcosimod, the first investigational therapy for neuropathic corneal pain, has shown significant pain reduction in clinical trials. The company aims to enhance its presence in the ophthalmic field through these presentations.
Read more →OKYOOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
OKYO Pharma will hold a Scientific Advisory Board meeting during the ASCRS Annual Meeting to discuss the clinical data for urcosimod, its lead candidate for treating neuropathic corneal pain. Dr. Pedram Hamrah will present findings from a Phase 2 study on urcosimod's efficacy and safety. This dual presence at ASCRS marks a significant milestone for the company as it prepares for further clinical trials.
Read more →OKYOOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting and New York, NY, April 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational
OKYO Pharma Limited announced it will conduct a Scientific Advisory Board meeting during the ASCRS Annual Meeting, featuring the presentation of data for its investigational therapy, urcosimod, aimed at treating neuropathic corneal pain. Dr. Pedram Hamrah will present findings from a Phase 2 study demonstrating the therapy's efficacy and safety. This conference is notable for its high-profile gathering of ophthalmology experts, and OKYO aims to refine its clinical strategies with insights from key opinion leaders. The company plans to initiate a Phase 2b/3 clinical trial in the near future, building on promising results from previous studies.
Read more →OKYOOKYO Pharma Announces Chief Development Officer and Director Acquires Shares
OKYO Pharma Limited announced that Chief Development Officer Gary Jacob acquired 30,980 shares, increasing his total to 108,920. The company is developing Urcosimod, which has shown promise in reducing neuropathic corneal pain (NCP) in recent trials. Following positive results from a Phase 2a trial, OKYO plans to initiate a Phase 2b/3 study this year.
Read more →About OKYO Pharma Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next OKYO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime